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Chronic pain is highly prevalent in multiple sclerosis (MS). Pain heterogeneity may contribute to 
poor treatment outcomes. The aim of this study was to characterize pain phenotypes distributions 
in persons with multiple sclerosis (MS), and compare pain phenotypes in terms of pain intensity, 
frequency of chronic overlapping pain conditions, and use and analgesic effects of different 
classes of pain medications. Data were collected via a national web-based survey with measures 
of neuropathic (painDETECT) and nociplastic pain (Fibromyalgia survey criteria), chronic 
overlapping pain conditions, and pain medication use and pain relief. In a sample of N=842 
adults with chronic pain and MS, the largest proportion (41%) showed evidence of nociceptive 
pain, 27% had mixed neuropathic/nociplastic pain, 23% had nociplastic pain, and 9% had 
neuropathic pain. Nociplastic pain was associated with significantly higher pain intensity and 
frequency of chronic overlapping pain conditions. Across all pain types, high frequency of pain 
medication use along with poor-modest pain relief wre reported. Cannabis use for pain was 
more common and pain relief ratings were higher among those with nociplastic pain, relative to 
nociceptive pain. Although NSAIDs use was highest among those with nociplastic pain (80%), 
pain relief ratings for NSAIDs were highest among those with nociceptive pain. These findings 
underscore the need for multidimensional assessment of pain in MS with greater emphasis on the 
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identification of pain phenotype. An improved characterization of pain as a multifaceted 
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Introduction 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) 
that affects approximately one million people in the United States and is the leading cause of 
non-traumatic disability in young adults [39,40,65,66]. Chronic pain is one of the most common 
and disabling symptoms in MS [1,14-16,18,24,25,30,36,38,45,47]. Unfortunately, current pain 
treatments do not provide sufficient or durable pain relief [56,57].  
Poor analgesic outcomes may result from pain heterogeneity in MS [17,18,54,55,57]. 
Many studies have focused on the prevalence of specific pain syndromes in MS (e.g., migraine, 
trigeminal neuralgia, Lhermitte's sign)[44,54,63], but an approach that focuses on describing 
pain subtypes with common underlying mechanisms could have greater therapeutic potential 
[2,13,44,56]. Attempts to characterize pain subtypes often employ time- and resource-intensive 
approaches to identifying pain mechanisms (e.g., quantitative sensory testing, imaging)[2,13].  
Alternatively, survey-based assessments have provided useful information about putative 
underlying pain mechanisms in populations outside of MS [7,8,23,28,42,64]. 
The International Association for the Study of Pain (IASP) has defined three categories 
of mechanistically-based pain types [43,62]. Neuropathic pain results from lesion or disease of 
the somatosensory nervous system [53]. Given the axonal injury associated with MS, pain is 
often assumed to be neuropathic in origin [27]. Nociceptive pain, in contrast, arises from 







activation of nociceptors in the periphery due to actu l or threatened tissue damage (including 
inflammation) as opposed to dysfunction in the somat sensory nervous system[26]; nociceptive 
pain is not well characterized in MS. Nociplastic pain arises from altered nociception despite no 
clear evidence of actual or threatened tissue damage c using the activation of peripheral 
nociceptors or evidence for disease or lesion of the somatosensory system causing the pain. This 
type of pain, often termed “centralized pain” or “central sensitization,” is thought to be due to 
CNS alterations in pain processing, as opposed to ong ing inflammation (nociceptive) or 
damaged neural pathways (neuropathic)[31,53,62].  
To date, the majority of work on pain in persons with MS has focused on pain associated 
with focal demyelinating lesions [44], with little attention given to concomitant 
nociceptive/inflammatory or nociplastic mechanisms, or differences in perceived treatment 
effects related to pain mechanisms. One study of the natural history of pain in MS indicated that 
those with chronic pain went on to develop more widespread pain over time (a characteristic of 
central sensitization)[74], but an examination of nciplastic pain in MS has not been undertaken. 
Work to identify subgroups with different underlying pain mechanisms will likely improve pain 
outcomes in MS by providing opportunity to tailor therapies to an individual’s specific type(s) of 
pain [2]. 
 To address gaps in knowledge about pain phenotypes in MS, we conducted a nation-wide 
survey to: 1) characterize distribution of neuropathic, nociceptive, nociplastic, and mixed 
neuropathic/nociplastic pain in those with chronic pain and MS; 2) examine whether level of 
pain intensity and prevalence of chronic overlapping pain conditions [37] differ between pain 
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Prior to study initiation, the protocol was submitted to the University of Michigan (UM) 
Medical Institutional Review Board; the study was deemed to meet federal and institutional 
criteria for exempt human subjects research. Survey data was collected through Qualtrics, a 
HIPAA compliant online research tool that allows for direct data entry by study participants and 
provides real-time data export and automated accrual report features [49]. Individuals who 
completed the survey had the option of entering a raffle to win one of twenty $100 gift cards.  
 
Study Sample 
 Study inclusion criteria included a self-reported MS diagnosis and age 18 years or older. 
There were no other inclusion or exclusion criteria, as the goal was to survey a diverse sample of 
adults with MS from across the US. Participants were r cruited through 1) an existing research 
registry at UM of people with medically documented-MS, 2) posting of the study survey link on 
the UM research website www.UMHealthResearch.org, and 3) via a National MS Society 
listserv email, which distributed the survey link nationwide to approximately 79,100 email 
addresses (~44,000 emails were opened). Data were collected between December 5, 2019 and 












The online survey included an in-depth demographic questionnaire (e.g., age, self-
reported biological sex and gender, education level, income, marital status, employment status, 
state of residence) as well the following validated s lf-report measures. To evaluate the accuracy 
of self-report of MS, surveys items assessing source of MS diagnosis (e.g., physician specialty), 
prior diagnostic workups, and current use of disease modifying therapy were also administered.  
 
Neuropathic Pain.  
Neuropathic pain was assessed using the painDETECT questionnaire (PD-Q), a 13-item 
screening survey to determine the presence/severity of pain of neuropathic origin [20]. The PD-Q 
assesses current average and worst pain intensity over the past 4 weeks (rated on an 11-point 
numeric rating scale of 0-10) as well as the presence of neuropathic pain qualities (e.g. burning 
sensation, tingling/prickling sensations; rated on a Likert scale from 0 [never] to 5 [very 
strongly]). Pain duration/pattern and radiation of pain are also assessed. The total score ranges 
from -1 to 38, with higher scores indicative of higer likelihood of neuropathic pain origin. 
Scores ≤12 indicate that a neuropathic component of pain is unlikely, scores between 13 and 18 
are ambiguous, and scores ≥ 19 indicate that a neuropathic component of pain is likely. 
 
Nociplastic Pain (Centralized Pain).  
The degree of centrally enhanced pain processing was assessed using the American 
College of Rheumatology (ACR) 2011 Fibromyalgia (FM) Survey Criteria [6,70,71]. This 
survey includes the number of painful body regions using the Michigan Body Map (0-19) and 
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continuously scaled metric (ranging between 0-31) can be used as a proxy index for central 
sensitization or can be used to indicate likely fibromyalgia with a cut-point of >13 [71].  This 
survey has been previously used to quantify centralized pain in other clinical populations 
[7,28,41], relates strongly to functional neuroimaging findings in nociplastic pain [3,32], and is a 
robust predictor of both pain and disability [68,69,72,73].  
 
Pain intensity 
Pain intensity was assessed with the PROMIS Pain Inte sity 3a [10], a 3-item measure 
that assesses worst and average pain in the past 7 d ys as well as current pain. The item scores 
were summed, and the total scale score transformed into a normative T-Score metric, with a 
Mean=50, Standard Deviation=10. Higher scores are indicative of higher pain intensity. 
 
Chronic Overlapping Pain Conditions. 
Measures that screen for three common chronic overlapping pain conditions (migraine, 
temporomandibular disorders [TMD], pelvic pain) [37] were administered. The three-item ID 
MigraineTM was used to screen for presence of migraine [34]. Endorsement of at least 2 of the 
three symptoms (nausea, photophobia, and headache-relat d disability) has been shown to have 
excellent sensitivity, specificity, and predictive alue relative to identifying migraine as well as 
excellent test-retest reliability [34]. Presence of likely TMD was assessed with a validated 3-item 
screening survey, the 3Q/TMD [35]. For this instrument, a score of 3 affirmative responses on 
two jaw pain items and one jaw dysfunction item indicates a conservative estimate of TMD risk. 
Presence of pelvic pain was assessed with a single Yes/No item, “Do you have persistent or 









Pain Medication Use and Associated Relief 
 A survey of pain medication use and relief was designed for this study. Current use of 
cannabinoids for medical purposes was collected. Respondents were also asked to endorse if they 
had used any of the following medications in the past month to manage any pain that was 
reported in the survey (selecting all that applied): non-steroidal anti-inflammatories (NSAIDs), 
opioids, anticonvulsants, selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), antispasmodics, steroids, and benzodiazepines. For 
each drug category, a list of example medications wa  provided on the survey. Respondents rated 
how much pain relief the medication provided on a 0 (no pain relief) to 10 (complete pain relief) 
numeric rating scale.  
 
Data Analysis 
Demographic and clinical characteristics of the sample were summarized as mean 
(standard deviation [SD]) and/or median (Interquartile ange [IQR]) for continuous variables, 
and frequency and proportion for categorical variables. Chi-squared tests were used to compare 
frequency of chronic overlapping pain conditions and use of different pain medications by pain 
subtype group. One-way analysis of variance (ANOVA) was used to compare mean PROMIS 
pain intensity T-scores and reported pain relief from different pain medications by different pain 
subtype groups. In cases where the omnibus ANOVA test was significant, post hoc multiple 
comparison Tukey HSD tests were conducted to examine pair-wise comparisons of pain intensity 
and pain relief ratings across the pain subtypes. Standardized effect sizes (Cohen’s d) were 










A total of 1,220 individuals representing 49 US states (except Wyoming) and the District 
of Columbia accessed the survey, indicated an MS diagnosis, and were invited to continue the 
survey. Analyses were completed on the 842 (69%) respondents who endorsed chronic pain 
(lasting at least three months) and who had scores (non-missing data) on the painDETECT and 
FM Survey Criteria. Those whose data were included in the analyses were statistically 
significantly older (Mincluded=51.83±11.98 [standard deviation follows all ± symbols hereafter], 
Mexcluded=49.77±12.84; F(1,1216) = 7.3, p = 0.007) but were not significantly different in terms 
of sex distribution (p=0.67). Descriptive statistics for the study sample are in Table 1.  
Distribution characteristics for all variables subjected to ANOVA tests (e.g., PROMIS pain 
intensity, pain relief scores) met normality criteria for conducting parametric statistical tests (all 
skew values <|.76|, all kurtosis values <|1.2|).  
 
Distribution of pain subtypes 
 On the ACR FM Survey Criteria (measure of centralized pain), the sample mean was 
12.19±5.65 and the median was 12 (IQR=8,16; See Figure 1.). Using the ACR FM Survey 
Criteria cut-point of ≥13, 346 (41.1%) of the sample scored positive for FM.  
 For the measure of neuropathic pain, the painDETECT, the sample mean was 15.73±8.18 
and the median=16 (IQR=10, 21; See Figure 2.). Most of the sample did not show strong 
evidence of neuropathic pain, with 303 (36.0%) scoring the range indicating an unlikely 
neuropathic component, 234 (27.8%) scoring in the Unclear/Ambiguous range, and 305 (36.2%) 
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 Using the median score on the ACR FM Survey Criteria (i.e., 12) and the positive cut-
point on the painDETECT (≥19) to identify probable pain phenotypes in this sample (Figure 3), 
the largest subgroup showed low scores on measures of both neuropathic and nociplastic pain 
(n=341, 40.5%) and was labeled “nociceptive type”. The next largest subgroup scored high on 
measures of both neuropathic and nociplastic pain (n=226, 26.8%) and was labeled “mixed 
type”. The group that reported pain that did not show neuropathic characteristics but scored high 
on the FM Survey (n=196, 23.3%) was labeled “nociplastic type”. The smallest subgroup, which 
consisted of people with MS who showed evidence on the painDETECT of probable neuropathic 
pain but no evidence of nociplastic pain (n=79, 9.4%), was labeled “neuropathic type”.  
 
Pain Intensity and Chronic Overlapping Pain Conditions 
 The pain subtypes differed significantly in terms of PROMIS pain intensity T-scores 
(F(3, 841) = 123.11, p <0.001). The nociceptive type had the lowest (Mean=44.98±6.89) and the 
mixed neuropathic/nociplastic type had the highest (Mean=55.06±5.77) average pain intensity. 
The neuropathic (Mean=50.82±6.02) and nociplastic types (Mean=50.71±5.59) had nearly 
identical average pain scores. Post-hoc multiple comparison tests revealed that all pain subtypes 
were significantly different from each other in terms of pain intensity scores (all p <0.001), with 
the exception of no significant difference between n uropathic and nociplastic subtypes (p = 
0.99; Cohen’s d = 0.02). Large differences in mean pain scores were obs rved between the 
nociceptive and neuropathic (Cohen’s d = 0.90), nociplastic (Cohen’s d = 0.91), and mixed pain 
subtypes (Cohen’s d = 1.58). Medium effects for mean pain differences were observed between 
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 Migraine was the most common chronic overlapping pain condition, followed by chronic 
pelvic pain; TMD was relatively rare. Prevalence of chronic pain conditions significantly 
differed by pain subtype (Table 2); in all cases, the mixed neuropathic/nociplastic pain type 
reported the highest frequency of chronic pain syndromes. Nociceptive type showed the lowest 
frequency of chronic overlapping pain conditions, with the exception of chronic pelvic pain, for 
which neuropathic pain type had the lowest frequency.   
 
Pain Treatments  
Non-steroidal anti-inflammatory drugs were the most commonly used (66.5%) and 
steroids the least commonly used (6.5%) medications f r analgesia across all pain types (see 
Table 3). For all pain medications, frequency of use signif cantly differed across the pain 
subtypes. Participants with high centralized forms of pain – nociplastic or mixed 
nociplastic/neuropathic pain – most frequently repoted use of cannabinoids, opioids, SNRIs, 
SSRIs, antispasmodics, and benzodiazepines. In contrast, participants categorized with the 
nociplastic pain type used NSAIDS 10% more frequently than the other groups. For 
anticonvulsants, those with the nociceptive pain type reported use frequencies~15% lower than 
the other three groups. Steroid use, although uncommon in general, was highest for those with 
any type of neuropathic pain – either alone or with nociplastic pain (mixed type).  
Narcotic pain medications received the highest average pain relief ratings 
(Mean=6.99±1.78, Median=7.00, IQR=6,8), followed closely by cannabinoids 
(Mean=6.29±2.17, Median=7.00, IQR=5,8). SSRIs were associated with least pain relief 
(Mean=2.72±3.12; Median=1, IQR=0,5) across all pain types. Analgesic ratings significantly 
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significantly higher for those with mixed pain compared to neuropathic pain (Tukey’s HSD p = 
0.02; Cohen’s d = 0.65), and relief ratings for NSAIDS were significantly higher for those with 
nociceptive pain compared to nociplastic (p = 0.001; Cohen’s d  = 0.41) and mixed pain subtypes 
(p < 0.001; Cohen’s d = 0.70) and for those with nociplastic pain compared to mixed pain (p = 
0.04; Cohen’s d = 0.30). Comparisons of pain relief ratings for benzodiazepines were 
underpowered due to low frequency of use and did not reveal statistically significant differences, 
despite substantial mean differences, indicating that t e neuropathic type rated this class of drugs 
2.32 points higher in terms of pain relief relative to nociceptive type (Cohen’s d = 0.82), 2.84 
points higher relative to nociplastic type (Cohen’s d = 1.02), and 1.96 points higher relative to 
mixed pain type (Cohen’s d= 0.78) on the pain relief scale.  
 
Discussion 
This is the first study to characterize pain phenotypes in MS within the IASP-defined 
mechanistically-based framework, and to compare pain henotypes in terms of pain intensity, 
chronic overlapping pain conditions, and use of/perceived analgesia of commonly used 
pharmacological therapies. The pattern we identified in MS is similar to that seen with other 
autoimmune disorders [12,46], where nociceptive pain is the most common underlying pain 
descriptor but a sizable proportion of individuals l o have nociplastic or mixed 
neuropathic/nociplastic pain types. In this sample, it was relatively uncommon for individuals to 
score high solely on the measure of neuropathic pain wh le not also scoring high on the measure 
of nociplastic pain. This suggests that identification of neuropathic pain alone may be 
insufficient to fully characterize pain for many ind viduals with MS, who may also demonstrate 
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Nociceptive pain has been recognized as one pain subtype in MS, often associated with 
postural problems, deconditioning, and/or muscle spasms [52,57]. However, the prominent focus 
on neuropathic pain in MS has contributed to lack of understanding of the scope and nature of 
nociceptive pain in MS. Given the relatively high prevalence of nociceptive pain in our sample 
(41%; indicated by neither neuropathic nor nociplastic pain characteristics), it is critical to gain a 
better understanding of nociceptive pain with an eye toward optimizing treatment for this pain 
subtype. Identification of patients with primarily nociceptive pain could enhance the chance of 
analgesic success. It is important to note that, due to our process of identifying nociceptive pain 
by process of elimination from the other pain categories, we may have underestimated the 
proportion of our sample with of pain of nociceptive origin; it is likely that mixed pain in MS 
also includes overlap of nociceptive pain with neuropathic and/or nociplastic in the same 
individual [19,21,61]. 
Nearly 60% of the sample had evidence of predominantly nociplastic pain, neuropathic 
pain, or a combination of both. This finding is not surprising, given the widespread CNS damage 
associated with MS and associated changes to the somatosensory system and pain processing. 
Yet, while neuropathic pain is commonly studied in MS, there have been no known 
investigations of centralized (nociplastic) pain, as it is currently defined, in MS. However, 
allodynia, perceived pain in response to a non-painful stimuli and a common feature of 
centralized pain, has been previously identified in patients with MS and chronic pain [58,59]. 
Further examination of two likely scenarios of nociplastic pain in MS – nociplastic pain 
occurring prior to the onset of MS or nociplastic pain developing after onset of MS – is 
warranted; in particular, examination of possible contributions of MS CNS lesions to central 
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Results for pain intensity and overlapping pain conditions were consistent with our 
expectations. We found a graded increase in pain inte sity when going from the group with 
nociceptive pain to those with elements of nociplastic pain. This is expected as nociplastic pain is 
thought to be due to CNS pain sensitization/amplification, and this same finding is noted when 
phenotyping based on pain mechanisms in rheumatic and other autoimmune disorders [5,7].  
Also as expected, chronic overlapping pain conditions were reported more frequently in those 
with nociplastic pain type. Though these pain conditions are diagnostically distinct, they share 
many similar characteristics (e.g., fatigue, mental fog, sleep problems), frequently co-occur, and 
are considered to be different manifestations of a common cause – pain amplification due to 
central sensitization [37,67]. This consideration highlights an understudied overlap between 
characteristics of MS and chronic overlapping pain co ditions, including FM. Significant 
problems with chronic pain, fatigue, cognitive dysfunction, depressed mood, and poor sleep are 
shared features of both MS and FM. The measure of pain centralization, the ACR FM survey 
criteria, includes a number of these symptoms – fatigue, sleep, and cognition - in the calculation 
of the total score. This overlap could complicate th  interpretation of FM survey criteria scores in 
a sample of people with MS. It is possible that classification of degree of central sensitization 
and classification of “positive” FM cases are overestimated because of this similarity in 
symptomology. It is also plausible that a significant proportion of people with MS truly have 
nociplastic pain, with some of these having a diagnosis of comorbid FM. Given our de-emphasis 
of identifying specific syndromes, we would argue for more of a focus on detecting elements of 
central sensitization mechanisms rather than on the FM diagnosis per se [69].  
 This study has important clinical value, laying the foundation for improving our ability to 
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efforts are underway to advance personalized pain therapy by phenotyping pain using the 
painDETECT [22,51], and painDETECT scores have been shown to predict treatment response 
in diabetic neuropathy[4] and chronic low back pain[50]. Similarly, prior research has shown 
that scores on the FM survey predict outcomes following knee or hip arthroplasty[8] and opioid 
consumption following surgery[28,33]. Nociplastic pain conditions such as FM are not thought 
to be responsive to NSAIDs or other anti-inflammatory drugs, and instead preferentially respond 
to centrally acting analgesics such as gabapentinoids, tricyclics, serotonin norepinephrine 
reuptake inhibitors, and cannabinoids [11]. Our findings are partially consistent with these 
previous observations. We found greater self-reportd analgesic effectiveness from NSAIDS for 
nociceptive pain type and from cannabinoids for mixed pain and neuropathic types. Armed with 
this information, clinicians may be supported in identifying the most appropriate initial 
pharmacotherapy treatment plan for the presenting pain icture. For example, successfully 
identifying pain of nociceptive origin spares the patient medications indicated for neuropathic 
pain that may offer an unfavorable benefit/risk profile. Given that patients with MS are 5 times 
more likely to receive a neuropathic pain medication han patients without MS [9], identifying 
those for whom this type of pain medication is not i dicated seems particularly critical. Across 
pain phenotypes, survey responses indicate high utilization of multiple classes of analgesic 
medication to manage chronic pain in MS and ratings that suggest poor to modest pain relief 
across the medication categories. NSAIDs have been us d for musculoskeletal pain or to address 
pain flares during MS exacerbations, but are more often indicated as co-medications with other 
analgesic categories that target neuropathic pain [48,57]. Higher use of cannabinoids in those 
with nociplastic pain either alone or along with neuropathic pain (mixed pain), is consistent with 
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centralization reported higher use of cannabis [52]. Although these initial findings indicate that 
medications may have different analgesic effects based on pain phenotype, the ability to predict 
treatment response from survey scores needs to be tested in MS. 
This study focused on pharmacological pain treatmens, but pain phenotypes could 
respond differently to physical and psychological therapies as well. The nociceptive-dominant 
pain subgroup may be driven by a variety of musculoskeletal or inflammatory nociceptive 
sources of pain that historically respond well to non-pharmacological management approaches, 
including physical or occupational therapy, that target biomechanical pain generators. There is 
mounting evidence supporting the effectiveness of psychological therapies to manage symptoms 
in both MS and FM and demonstrating that psychological interventions can alter how the brain 
processes sensory information [29,60]. Together these bodies of literature support a shared CNS 
mechanism of pain in both MS and FM and suggest a need for future research to investigate if 
and how non-pharmacological treatments may be effective for nociplastic pain in people with 
MS and chronic pain.  
 
Study Strengths and Limitations 
 The large nationwide sample, use of validated measur s, good response rate, and low 
level of missing data from those who started the survey are strengths of this study. The sample 
was predominantly female and white, which limits generalizability. Use of the National MS 
Society email listserv to recruit most study participants may also limit the generalizability of the 
findings. Given the lack of available measures to identify nociceptive pain, this pain type was 
identified by exclusion, which limited our ability o understand mixed pain characterized by co-
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both sensory and emotional aspects of the pain experi nc ; the focus of this paper to attempt to 
characterize the biological and neurobiological mechanisms of chronic pain in MS does not 
incorporate potential emotional facets of pain phenotypes. Future research that characterizes MS 
pain phenotypes based on both sensory and emotional characteristics, and in the context of other 
symptoms, may help to further clarify our understanding of pain in MS and how best to treat it.   
 
Conclusion 
Results suggest that people with chronic pain and MS most commonly experience pain 
that has characteristics of nociceptive mechanisms or a mixed pain state, which can be described 
as a combination of nociceptive, nociplastic, and/or neuropathic pain characteristics. Pain that 
can be described as having purely neuropathic charateristics was relatively rare. This work 
highlights the need to assess pain phenotype in persons with chronic pain and MS to move 
toward a precision model of pain management in MS. 
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Figure Captions.  
 
Figure 1. Distribution of FM Survey Criteria Scores (N=842) 
Figure 2. Distribution of painDETECT scores (N=842) 
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Table 1. Sample descriptive statistics (N=842) 
Sex N (%) 
Male  168 (20.0%) 
Female 674 (80.0%) 
Gender N (%) 
Male  168 (20.0%) 
Female 672 (79.8%)  
Transgender 1 (0.1%) 
Gender variant / non-conforming 1 (0.1%) 
Race N (%) 
White 768 (91.2%) 
Black or African American 43 (5.1%) 
American Indian or Alaska Native 4 (0.4%) 
Asian 6 (0.7%) 
Native Hawaiian or other Pacific Islander 1 (0.1%)  
Bi /multi-racial 11 (1.3%) 
MS type N (%) 
Relapsing remitting 561 (66.6%) 
Secondary progressive 137 (16.3%) 
Primary progressive 78 (9.3%) 
Progressive relapsing 19 (2.3%) 
Not sure 47 (5.6%) 
Time since MS diagnosis N (%) 
<1 year 50 (5.9%) 
1-5 years 183 (21.7%) 
6-10 years 164 (19.5%) 
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16-20 years 125 (14.8%) 








Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2020



























































Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            2020
 
 
Table 3. Differences by pain subtype in reported use of pain medications within the past month, and 
























pain relief  
5.87(2.34)A,B 5.21(2.67)A 6.39(1.93)A,B 6.75(2.02) B 
















pain relief 5.88(2.45)A 4.98(2.77)A, B, C 4.89(2.40)B 4.16(2.14)C 
F(3,556) = 
15.45, 
















7.23(1.52) 7.80(1.32) 7.00(1.84) 6.71(1.96) 
F(3,139) = 1.38, 
















5.99(2.83) 5.79(2.49) 5.67(2.33) 5.24(2.47) 
F(3,271) = 1.25, 





















5.32(2.49) 4.83(2.99) 4.18(2.57) 4.43(2.99) 
F(3,115) = 1.04, 
















2.82(3.39) 3.43(3.78) 2.06(2.84) 3.21(2.98) 
F(3,154) = 1.30, 
















5.88(2.26) 5.71(2.91) 5.63(2.29) 5.57(2.15) 
F(3,304) = 0.33, 
















5.78(3.27) 5.88(2.85) 5.33(2.96) 5.78(2.94) 
F(3,54) = 0.09, 
















4.31(3.24) 6.63(2.33) 3.79(3.17) 4.67(2.66) 
F(3,125) = 2.11, 
p = 0.10 
Note.  A, B, C = Values with different subscripts indicate significant pair-wise mean differences. NSAID 
= non-steroidal anti-inflammatory drug; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = 
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